A cost analysis of hematopoietic colony-stimulating factors
The administration of hematopoietic colony-stimulating factors (CSFs) to reduce the severity and duration of neutropenia associated with systemic chemotherapy has become widespread, although the appropriate use of these agents has not yet been fully defined. A cost model based on decision theory is presented for three therapeutic choices in these patients: no CSF, prophylactic CSF, and therapeutic CSF. Baseline probabilities were derived from a prospective, randomized, placebo-controlled trial of C-CSF in patients receiving systemic chemotherapy. Application of the model to institutionally generated cost figures provides comparative estimates of excess cost favoring the prophylactic use of CSFs. Model thresholds were calculated based on sensitivity analysis comparing no CSF to prophylactic CSF, and therapeutic CSF to prophylactic CSF. Guidelines are provided based on this model that are consistent with those adopted by the American Society of Clinical Oncology.
Duke Scholars
Published In
Publication Date
Volume
Issue
Start / End Page
Related Subject Headings
- Oncology & Carcinogenesis
- 1112 Oncology and Carcinogenesis
Citation
Published In
Publication Date
Volume
Issue
Start / End Page
Related Subject Headings
- Oncology & Carcinogenesis
- 1112 Oncology and Carcinogenesis